Spirox

Spirox Short-term Debt

The Short-Term Debt of Spirox (3055.TW) as of Nov 14, 2026 is 10.60 M TWD. In the previous year, Short-Term Debt was 69.78 M TWD — a change of -84.81% (lower).

Short-term Debt

10.60 MTWD

YoY

-84.81%

Last updated:

Short-Term Debt of Spirox is 2025 10.60 M TWD. Short-Term Debt of Spirox was 2024 69.78 M TWD. It decreases by -84.81% lower compared to the previous year.

The Spirox Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2018
9.20 M TWD
Jan 1, 2019
1.55 B TWD
Jan 1, 2020
2.02 B TWD
Jan 1, 2021
643.88 M TWD
Jan 1, 2022
239.31 M TWD
Jan 1, 2023
352.97 M TWD
Jan 1, 2024
69.78 M TWD
Jan 1, 2025
10.60 M TWD
The Spirox Short-term Debt history
YEARShort-term DebtYoY
10.60 MTWD-84.81%
69.78 MTWD-80.23%
352.97 MTWD+47.49%
239.31 MTWD-62.83%
643.88 MTWD-68.15%
2.02 BTWD+30.87%
1.55 BTWD+16,693.63%
9.20 MTWD—
0.00TWD-100.00%
92.34 MTWD+19.92%
77.00 MTWD+208.00%
25.00 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Spirox Stock analysis

What does Spirox do? The Spirox Corporation is a company that was founded in 2007 and is headquartered in Menlo Park, California. The company operates in the medical technology industry and specializes in the development of products for nasal breathing. The mission of Spirox is to help people who have difficulty breathing through their nose. The company has recognized that many people have difficulty breathing through their nose due to congestion or other issues. Breathing through the mouth, however, can lead to a range of health problems such as dry mouth, sleep apnea, and respiratory infections. Therefore, Spirox has set out to develop innovative solutions to facilitate nasal breathing. Spirox's products include both implantable and non-implantable solutions. The company has a small but effective product portfolio consisting of two products: the Latera Nasal Stent and the AeroForm Nasal Stent. The Latera Nasal Stent is used to permanently open the nasal passages and facilitate breathing. The placement of the stent is a minimally invasive procedure that is typically performed on an outpatient basis. The Latera Nasal Stent is inserted and secured in the nasal wings to allow for better airflow through the nostrils. The stent is made of polydioxanone (PDO), a biocompatible polymer fiber that is absorbed by the body. Spirox's second product, the AeroForm Nasal Stent, is a non-implantable nasal stent used for temporary relief of nasal breathing. The AeroForm is a soft stent made of a flexible polymer material. It is inserted into the nasal passages and forms a gentle expansion to facilitate nasal breathing. As a company, Spirox focuses on collaboration with specialists and clinics to ensure that their products have high success rates. The company has established a partnership with the American Academy of Otolaryngology - Head and Neck Surgery (AAO-HNS) to advance scientific research and development in the nasal breathing industry. Spirox is led by experienced executives from the medical technology industry. The CEO, Duke Rohlen, has over 20 years of experience in leading medical technology companies such as Inspire Medical Systems and CV Ingenuity. The board team also includes Elektra Papadopoulos as Chair of the Board, who has worked at Hologic and Boston Scientific, among others. Although Spirox is a relatively small company, it has already received several awards. In 2017, the company was awarded the Red Herring Top 100 North America Award, which recognizes companies that are leading in the innovation industry. Overall, Spirox is an emerging company in the medical technology industry that offers innovative solutions to facilitate nasal breathing. Through collaboration with doctors and clinics and a focus on scientific research, the company aims to improve the success and effectiveness of its products. Spirox is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Spirox stock

Short-Term Debt of Spirox is 10.60 M TWD in 2025.

Short-Term Debt of Spirox changed from 69.78 M TWD to 10.60 M TWD, representing a -84.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt Spirox since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's Spirox historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Spirox

All Key Metrics — Spirox